ATLG is a polyclonal anti–T-cell IgG that depletes T cells via complement-mediated lysis, ADCC, and apoptosis after binding T-cell antigens. HLA-DR+ cells (e.g., APCs) are not directly targeted; their activity is reduced indirectly by loss of T-cell help and inflammatory cytokines.